(MedPage Today) — In the decade since palbociclib (Ibrance) received FDA approval, results from multiple clinical trials have provided a strong evidence base to make cyclin-dependent kinase (CDK)4/6 inhibitors, in combination with endocrine therapy…
Source link : https://www.medpagetoday.com/spotlight/sabcs-breast-cancer/119177
Author :
Publish date : 2025-12-23 20:32:00
Copyright for syndicated content belongs to the linked Source.
